Patents by Inventor Friedmund Neumann

Friedmund Neumann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men
    Patent number: 6696432
    Abstract: The present invention concerns the combination of dehydroepiandrosterone (DHEA) and at least one aromatase inhibitor and the use of such a combination to produce a medicament for treating relative and/or absolute androgen deficiency in men. Selective aromatase inhibitors such as atamestan, formestan, pentrozol, aramidex, fadrozol, CGS 20267 and/or vorozol, are preferred for producing the medicament according to the invention.
    Type: Grant
    Filed: November 3, 1998
    Date of Patent: February 24, 2004
    Assignee: Schering Aktiengesellschaft
    Inventors: Jörg Elliesen, Albert Radlmaier, Ursula Habenicht, Friedmund Neumann
  • Methods of treating androgen deficiency in men using selective aromatase inhibitors
    Patent number: 5861389
    Abstract: Male menopause is characterized by significant decreases in serum levels of bioavailable androgens. The administration of aromatase inhibitors to men experiencing male menopause can remedy the relative androgen deficiency in men while at the same time approximating the physiological hormonal ratio of androgens to estrogens.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: January 19, 1999
    Assignee: Schering Aktiengesellschaft
    Inventors: Albert Radlmaier, Ursula-Friederike Habenicht, Friedmund Neumann
  • Use of aromatase-inhibitors for prophylaxis and/or treatment of benign prostatic hyperplasia
    Patent number: 4596797
    Abstract: Aromatase-inhibitors are used in a method of prophylaxis and/or treatment by therapy of prostatic hyperplasia. Pharmaceutical preparations suitable for such a use comprise an aromatase-inhibitor. A particularly preferred aromatase-inhibitor is, for example, testolactone.
    Type: Grant
    Filed: May 13, 1985
    Date of Patent: June 24, 1986
    Assignee: Schering Aktiengesellschaft
    Inventors: Hans-Udo Schweikert, Ulf Tunn, Theodor Senge, Friedmund Neumann
  • Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate
    Patent number: 4310523
    Abstract: A pharmaceutical composition comprising an anti-estrogen and an antigonadotropically effective anti-androgen, e.g., in a weight ratio of anti-estrogen to anti-androgen of essentially 2:1 to 1:10 is effective for the prophylaxis and therapy of prostate hyperplasia. Suitable anti-estrogens include, for example, tamoxifen. Antigonadotropically active anti-androgens preferably are steroids having anti-androgenic and progestational properties, e.g., cyproterone acetate.
    Type: Grant
    Filed: October 10, 1980
    Date of Patent: January 12, 1982
    Assignee: Schering Aktiengesellschaft
    Inventor: Friedmund Neumann
  • Novel agents and novel methods for treatment of climacteric disturbances
    Patent number: 4145416
    Abstract: Relief from climacteric disturbances is achieved by administration of first a combination of an estrogen of type 1 and an estrogen of type 2, approximately in a ratio of 2:1 to 1:8, daily over 10-12 days; then a combination of an estrogen of type 1 and an estrogen of type 2, approximately in a ratio of 2:1 to 1:8, and a progestogen, daily over 9-11 days; and thereafter an estrogen of type 2, or a placebo, daily over 6-8 days.
    Type: Grant
    Filed: September 27, 1977
    Date of Patent: March 20, 1979
    Assignee: Schering, A.G.
    Inventors: Ursula Lachnit-Fixson, Friedmund Neumann
  • Novel agents and methods for treatment of climacteric disturbances
    Patent number: 4076811
    Abstract: Reliable relief of physical and psychological menopausal disturbances is achieved by administering a combination of estradiol estrogen or derivatives of estradiol (type 1) and estriol or a derivative of estriol (type 2) in a ratio of approximately 1 : 1 to 1 : 10 for 21 days and thereafter an estrogen of type 2, a placebo or no hormone for 7 days. Administration of the dosage for 28 days permits adaptation to the normal cycle of the female.
    Type: Grant
    Filed: June 23, 1976
    Date of Patent: February 28, 1978
    Assignee: Schering Aktiengesellschaft
    Inventors: Ursula Lachnit-Fixson, Friedmund Neumann
  • 1,3-Oxygenated 8.alpha.-estratrienes
    Patent number: 3951959
    Abstract: 8.alpha.-Estratrienes of the formula ##SPC1##Wherein R is lower alkyl and X is an oxygen atom, a .beta.-hydroxy or .beta.-hydroxy-.alpha.-substituted or unsubstituted saturated or unsaturated hydrocarbon group, and the esters and ethers thereof, possess strong vaginotropic but only weak utertropic activity and are useful in the treatment of estrogenic deficiency conditions where uteral effects are not desired.
    Type: Grant
    Filed: July 12, 1974
    Date of Patent: April 20, 1976
    Assignee: Schering Aktiengesellschaft
    Inventors: Klaus Prezewowsky, Henry Laurent, Helmut Hofmeister, Rudolf Wiechert, Friedmund Neumann, Yukishige Nishino
  • 1,3-Oxygenated-8.alpha.-estratrienes
    Patent number: 3951958
    Abstract: 1,3-Dihydroxy-8.alpha.-estratrienes of the formula ##SPC1##Wherein R is lower-alkyl and --A--B is ##SPC2##Wherein R' is a saturated or unsaturated hydrocarbon group and R" is lower-alkyl, aralkyl or phenyl, and the esters and ethers thereof, possess strong vaginotropic but only weak utertropic activity and are useful in the treatment of estrogenic deficiency conditions where uteral effects are not desired.
    Type: Grant
    Filed: July 12, 1974
    Date of Patent: April 20, 1976
    Assignee: Schering Aktiengesellschaft
    Inventors: Klaus Prezewowsky, Henry Laurent, Helmut Hofmeister, Rudolf Wiechert, Friedmund Neumann, Yukishige Nishino
  • 17.alpha.-Ethinyl-18-methyl-19-nortestosterone esters
    Patent number: RE28690
    Abstract: A therapeutic compound for inhibiting ovulation comprising a 17-ester of 17.alpha.-ethinyl-18-methyl-19-nortestosterone wherein the said 17-ester group is formed from an aliphatic carboxylic acid having from six to 11 carbon atoms in the ester residue..Iaddend.
    Type: Grant
    Filed: July 19, 1974
    Date of Patent: January 20, 1976
    Assignee: Schering Aktiengesellschaft
    Inventors: Hans-Gunter Lehmann, Heinz Gibian, Rudolf Wiechert, Friedmund Neumann